Risk of complications within the cardiorenal axis is mitigable by choice of antidiabetes classes.Sulfonylureas and human insulin have been shown to have greater associations with these long-term outcomes, whereas GLP-1 receptor agonists and SGLT-2 inhibitors have evidence for slowing or preventing CV or renal disease. Accordingly, the latter two have been recommended as treatments of choice for patients with, or at risk, of these complications. This evidence concerns the gene SLC5A2 and kidney disorder.